EMEA Meningitis Diagnostic Testing Market

Meningitis Diagnostic Testing Market (Product Type: Latex Agglutination Tests, Lateral Flow Assay, PCR Assay, ELISA Tests, and Others; Panel Type and End-user) - Europe and Middle East & Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Europe and Middle East & Africa Meningitis Diagnostic Testing Market Outlook 2031

  • The EMEA meningitis diagnostic testing market was valued over US$ 55.95 Mn in 2020
  • It is estimated to expand at a CAGR of 3.7% from 2021 to 2031
  • The EMEA meningitis diagnostic testing market is expected to reach the value of US$ 83.51 Mn by the end of 2031

Analysts’ Viewpoint on Europe and Middle East & Africa Meningitis Diagnostic Testing Market

Companies in the EMEA meningitis diagnostic testing market are taking advantage of governments’ stimulus packages to stay financially afloat during the ongoing COVID-19 pandemic. Currently available rapid diagnostics tests (RDTs) to detect meningococcal meningitis are found to have a short shelf life. Hence, companies in the EMEA meningitis diagnostic testing market are increasing research to develop RDTs with good sensitivities and specificities. Rapid, accurate, and specific identification of the causative organism are necessary to ensure an effective public health response. Apart from diagnostic tests, healthcare companies are diversifying in the implementation of conjugate polysaccharide vaccines to revolutionize public health management.

New Kits Hold Potentials to Improve Molecular Diagnosis of Bacterial Meningitis

The technology of diagnostic kit for bacterial meningitis using real-time HRM PCR holds potential to improve clinical numbers. Companies in the EMEA meningitis diagnostic testing market should collaborate with researchers to develop new kits that help to cut down costs of molecular diagnosis of bacterial meningitis. Stakeholders are taking efforts to increase the availability of these kits amongst the common public and mainly at private laboratories.

Companies in the EMEA meningitis diagnostic testing market are increasing R&D in developing kits that make use of a single fluorophore to detect the target genes through melting temperature analysis of the bacterial target gene. It has been found that each gene detected has a different melting temperature, easily visualized in a graph at the end of the amplification.

Early Diagnosis of COVID-19 and Meningitis to Prevent Disease Spread

Common symptoms of COVID-19 and meningitis are creating concerns for both healthcare providers and the general public. Thus, robust diagnostic testing has become the need of the hour during the ongoing pandemic. Stakeholders in the EMEA meningitis diagnostic testing market are increasing the availability of products to meet healthcare needs of individuals.

In order to reduce stress on healthcare facilities, stakeholders in the EMEA meningitis diagnostic testing market are increasing awareness and facilitating early diagnosis to prevent the spread of diseases. They are maintaining optimum inventory levels to ensure continuity in supply chains. Companies are rethinking their manufacturing activities since financial situations have been squeezed for many. They are taking data-driven decisions to sustain volatile market sentiments.

Logistical Challenges in Africa Affect Clinical Numbers for Meningitis Diagnostic Testing

Transporting samples to laboratories have many logistical challenges in countries falling under the meningitis belt in Africa, as latex agglutination requires refrigeration and lab equipment. Moreover, this technique is dependent on a sample of spinal fluid from the patient taken by lumber puncture.

Participants in the market should collaborate with clinicians, medical practitioners, and labs to invest in training of medical staff or hire trained staff in primary healthcare settings and remote areas.

Molecular Diagnostic Assays Help Distinguish Between Different Bacteria

Bacterial meningitis is becoming one of the major causes of morbidity and mortality. Participants in the EMEA meningitis diagnostic testing market are taking advantage of this opportunity to enable rapid identification of the aetiological agent of meningitis. Such innovations are benefitting healthcare providers participating in clinical and public health management.

Since microbiological culture is complex, slow, and often impacted by prior antimicrobial treatment of the patient, companies in the EMEA meningitis diagnostic testing market are increasing the availability of molecular diagnostic assays for bacterial detection. Distinguishing between meningitis caused by meningococcus, pneumococcus, and others is becoming an important aspect of detection techniques.

PCR Tests Support Rapid Outbreak Detection in Africa

Rapid diagnostic tests are significantly changing the EMEA meningitis diagnostic testing market. Companies are offering new lateral flow tests for the diagnosis of Neisseria meningitides, MeningoSpeed, and other bacteria to support rapid outbreak detection in Africa. The microbial diagnosis of meningitis is currently based on culture or more frequently on polymerase chain reaction (PCR) tests carried out by national reference laboratories (NRLs) on a sample of cerebrospinal fluid (CSF).

PCR tests require the maintaining of sample in a cold chain in primary health care centers (PHCs) and during transportation to the NRL. However, this makes the early identification of circulating strains difficult. In order to reduce the time needed to detect circulating strains, healthcare companies are developing diagnostic tests that can be used at bedside.

Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market: Overview

  • Meningitis is an infection of the protective membranes that surround the brain and spinal cord. It can affect anyone, but is most common in babies, young children, teenagers, and young adults. Symptoms include fever, headache, stiff neck, seizures, and others. The various types of meningitis are viral meningitis, bacterial meningitis, and fungal meningitis.
  • Latex agglutination test is a passive agglutination test, wherein analytes (antigens) are adsorbed onto latex particles. The test has a range of specificity and sensitivity, ranging from 60% to 93% for various microorganisms (such as Streptococcus pneumonia, Hemophilus influenzae, and Neisseria meningitidis).
  • Lateral flow assay is also known as immunochromatographic test or dipstick assay. It is a paper-based test to detect analytes (antigens) in a complex mixture, wherein the sample to be analyzed is placed on a device and results are displayed within five to 30 minutes. These tests are widely used as point-of-care testing.

Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market: Key Drivers

  • Rise in demand for point-of-care services is anticipated to drive the meningitis diagnostic testing market in EMEA during the forecast period. Point-of-care services provide more accurate results in less time compared to traditional methods.
  • New, innovative technologies such PCR and next-generation sequencing are available in the market, providing a less expensive way for the diagnosis, prognosis, and therapy selection in patients during their treatment. This helps physicians frame appropriate therapeutic systems for patients suffering from the infectious disease.
  • In May 2018, BioGX B.V. launched Six CE-Mark tests for meningitis and antibiotic resistance. Meningitis test includes viral meningitis HSV/VZV, bacterial meningitis NSH, and bacterial meningitis ELGBS.

Market Segmentation: Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market

  • In terms of product type, the meningitis diagnostic testing market in EMEA has been classified into latex agglutination tests, lateral flow assay, PCR assay, ELISA tests, culture test, and others
  • Based on panel type, the meningitis diagnostic testing market in EMEA has been bifurcated into syndromic full multiplex panel and low plex panel
  • In terms of end-user, the meningitis diagnostic testing market in EMEA has been divided into hospitals, diagnostic laboratories, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The meningitis diagnostic testing market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market

  • Europe dominated the meningitis diagnostic testing market in EMEA in 2020, accounting for 87.9% share. Increase in health awareness, rise in expenditure on healthcare infrastructure, and surge in demand for better healthcare facilities fuel the growth of the market in Europe.
  • Germany is projected to be an attractive market from 2021 to 2031. The country is anticipated to account for significant share of the market in Europe during the forecast period. Growth of the market in Germany can be attributed to increase in research activities, rise in government funding for research & development, and surge in the number of biotechnology companies.

Major Players

  • The meningitis diagnostic testing market report concludes with the company profiles section, which includes key information about major players in the meningitis diagnostic testing market in EMEA
  • Leading players analyzed in the report include
    • Thermo Fisher Scientific, Inc.
    • Abbott Laboratories
    • BioFire Diagnostics
    • Bio-Rad Laboratories, Inc.
    • ELITechGroup
    • Fast Track Diagnostics Ltd. (Siemens Healthineers)
    • IMMY
    • Nanosphere (Luminex Corporation)
    • Qnostics
    • Seegene, Inc.
  • Each of these players has been profiled in the meningitis diagnostic testing market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 55.95 Mn

Market Forecast Value in 2031

US$ 83.51 Mn

Growth Rate (CAGR)

3.7%

Forecast Period

2021–2031

Historical Data Available for

2017–2019

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product Type
    • Latex Agglutination Tests
    • Lateral Flow Assay
    • PCR Assay
    • ELISA Tests
    • Culture Test
    • Others
  • Panel Type
    • Syndromic Full Multiplex Panel
    • Low Plex Panel
  • End-user
    • Hospitals
    • Diagnostic Centers
    • Others

Regions Covered

  • Europe
  • Middle East & Africa

Countries Covered

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Finland
  • Austria
  • Switzerland
  • Benelux
  • Norway
  • Poland
  • Rest of Europe
  • GCC Countries
  • South Africa
  • Rest of Middle east & Africa

Companies Profiled

  • Thermo Fisher Scientific, Inc.
  • Abbott Laboratories
  • BioFire Diagnostics
  • Bio-Rad Laboratories, Inc.
  • ELITechGroup
  • Fast Track Diagnostics Ltd. (FTD) – Siemens Healthineers
  • IMMY
  • Nanosphere (Luminex Corporation)
  • Qnostics
  • Seegene, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Europe and Middle East & Africa Meningitis Diagnostic Testing Market – Segmentation

TMR’s study on the meningitis diagnostic testing market in EMEA includes information divided into four segments: product type, panel type, end-user, and region. Changing industry trends and other market dynamics associated with these segments of the meningitis diagnostic testing market in EMEA are discussed in detail.

Product Type
  • Latex Agglutination Tests
  • Lateral Flow Assay
  • PCR Assay
  • ELISA Tests
  • Culture Test
  • Others
Panel Type
  • Syndromic Full Multiplex Panel
  • Low Plex Panel
End-user
  • Hospitals
  • Diagnostic Centers
  • Others
Region
  • Europe
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of EMEA meningitis diagnostic testing market?

EMEA meningitis diagnostic testing market is expected to reach the value of US$ 83.51 Mn by 2031

What is the anticipated CAGR of the EMEA meningitis diagnostic testing market in the forecast period?

EMEA meningitis diagnostic testing market to expand at a CAGR of 3.7% from 2021 to 2031

What are the key driving factors for the growth of the EMEA meningitis diagnostic testing market?

Meningitis diagnostic testing market in EMEA is driven by rise in healthcare expenditure led by surge in awareness about different healthcare programs and availability of cost-effective diagnostic methods.

Which is the rising prominent segment in the EMEA meningitis diagnostic testing market?

The lateral flow assay segment is projected to account for major share of the meningitis diagnostic testing market in EMEA during the forecast period.

Who are the key players in the EMEA meningitis diagnostic testing market?

Key players operating in the EMEA meningitis diagnostic testing market include Thermo Fisher Scientific, Inc., Abbott Laboratories, BioFire Diagnostics, Bio-Rad Laboratories, Inc., ELITechGroup

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Europe and Middle East & Africa Meningitis Diagnostic Testing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Key Success Factors for Top Players

        5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid /long term impact)

        5.3. Key Industry Developments (product launch, product approvals, business expansion, etc.)

        5.4. Regulatory Scenario

    6. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Product

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, By Product, 2017–2031

            6.3.1. Latex Agglutination Tests

            6.3.2. Lateral Flow Assay

            6.3.3. PCR Assay

            6.3.4. ELISA Tests

            6.3.5. Culture Test

            6.3.6. Others

        6.4. Market Attractiveness Analysis, By Product

    7. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Type, 2017–2031

            7.3.1. Syndromic Full Multiplex Panel

            7.3.2. Low Plex Panel

        7.4. Market Attractiveness Analysis, By Type

    8. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, By End-user, 2017–2031

        8.4. Market Attractiveness Analysis, By End-user

    9. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Region

        9.1. Key Findings

        9.2. Market Value Forecast, By Region

    10. Europe Meningitis Diagnostic Testing Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, By Product, 2017–2031

            10.2.1. Latex Agglutination Tests

            10.2.2. Lateral Flow Assay

            10.2.3. PCR Assay

            10.2.4. ELISA Tests

            10.2.5. Culture Test

            10.2.6. Others

        10.3. Market Value Forecast, By Type, 2017–2031

            10.3.1. Syndromic Full Multiplex Panel

            10.3.2. Low Plex Panel

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Hospitals

            10.4.2. Diagnostic Centers

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. Germany

                10.5.1.1. Market Value Forecast, by Product, 2017–2031

                    10.5.1.1.1. Latex Agglutination Tests

                    10.5.1.1.2. Lateral Flow Assay

                    10.5.1.1.3. PCR Assay

                    10.5.1.1.4. ELISA Tests

                    10.5.1.1.5. Culture Test

                    10.5.1.1.6. Others

                10.5.1.2. Market Value Forecast, by Type, 2017–2031

                    10.5.1.2.1. Syndromic Full Multiplex Panel

                    10.5.1.2.2. Low Plex Panel

                10.5.1.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.1.3.1. Hospitals

                    10.5.1.3.2. Diagnostic Centers

                    10.5.1.3.3. Others

            10.5.2. U.K.

                10.5.2.1. Market Value Forecast, by Product, 2017–2031

                    10.5.2.1.1. Latex Agglutination Tests

                    10.5.2.1.2. Lateral Flow Assay

                    10.5.2.1.3. PCR Assay

                    10.5.2.1.4. ELISA Tests

                    10.5.2.1.5. Culture Test

                    10.5.2.1.6. Others

                10.5.2.2. Market Value Forecast, by Type, 2017–2031

                    10.5.2.2.1. Syndromic Full Multiplex Panel

                    10.5.2.2.2. Low Plex Panel

                10.5.2.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.2.3.1. Hospitals

                    10.5.2.3.2. Diagnostic Centers

                    10.5.2.3.3. Others

            10.5.3. France

                10.5.3.1. Market Value Forecast, by Product, 2017–2031

                    10.5.3.1.1. Latex Agglutination Tests

                    10.5.3.1.2. Lateral Flow Assay

                    10.5.3.1.3. PCR Assay

                    10.5.3.1.4. ELISA Tests

                    10.5.3.1.5. Culture Test

                    10.5.3.1.6. Others

                10.5.3.2. Market Value Forecast, by Type, 2017–2031

                    10.5.3.2.1. Syndromic Full Multiplex Panel

                    10.5.3.2.2. Low Plex Panel

                10.5.3.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.3.3.1. Hospitals

                    10.5.3.3.2. Diagnostic Centers

                    10.5.3.3.3. Others

            10.5.4. Italy

                10.5.4.1. Market Value Forecast, by Product, 2017–2031

                    10.5.4.1.1. Latex Agglutination Tests

                    10.5.4.1.2. Lateral Flow Assay

                    10.5.4.1.3. PCR Assay

                    10.5.4.1.4. ELISA Tests

                    10.5.4.1.5. Culture Test

                    10.5.4.1.6. Others

                10.5.4.2. Market Value Forecast, by Type, 2017–2031

                    10.5.4.2.1. Syndromic Full Multiplex Panel

                    10.5.4.2.2. Low Plex Panel

                10.5.4.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.4.3.1. Hospitals

                    10.5.4.3.2. Diagnostic Centers

                    10.5.4.3.3. Others

            10.5.5. Spain

                10.5.5.1. Market Value Forecast, by Product, 2017–2031

                    10.5.5.1.1. Latex Agglutination Tests

                    10.5.5.1.2. Lateral Flow Assay

                    10.5.5.1.3. PCR Assay

                    10.5.5.1.4. ELISA Tests

                    10.5.5.1.5. Culture Test

                    10.5.5.1.6. Others

                10.5.5.2. Market Value Forecast, by Type, 2017–2031

                    10.5.5.2.1. Syndromic Full Multiplex Panel

                    10.5.5.2.2. Low Plex Panel

                10.5.5.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.5.3.1. Hospitals

                    10.5.5.3.2. Diagnostic Centers

                    10.5.5.3.3. Others

            10.5.6. Benelux

                10.5.6.1. Market Value Forecast, by Product, 2017–2031

                    10.5.6.1.1. Latex Agglutination Tests

                    10.5.6.1.2. Lateral Flow Assay

                    10.5.6.1.3. PCR Assay

                    10.5.6.1.4. ELISA Tests

                    10.5.6.1.5. Culture Test

                    10.5.6.1.6. Others

                10.5.6.2. Market Value Forecast, by Type, 2017–2031

                    10.5.6.2.1. Syndromic Full Multiplex Panel

                    10.5.6.2.2. Low Plex Panel

                10.5.6.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.6.3.1. Hospitals

                    10.5.6.3.2. Diagnostic Centers

                    10.5.6.3.3. Others

            10.5.7. Poland

                10.5.7.1. Market Value Forecast, by Product, 2017–2031

                    10.5.7.1.1. Latex Agglutination Tests

                    10.5.7.1.2. Lateral Flow Assay

                    10.5.7.1.3. PCR Assay

                    10.5.7.1.4. ELISA Tests

                    10.5.7.1.5. Culture Test

                    10.5.7.1.6. Others

                10.5.7.2. Market Value Forecast, by Type, 2017–2031

                    10.5.7.2.1. Syndromic Full Multiplex Panel

                    10.5.7.2.2. Low Plex Panel

                10.5.7.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.7.3.1. Hospitals

                    10.5.7.3.2. Diagnostic Centers

                    10.5.7.3.3. Others

            10.5.8. Norway

                10.5.8.1. Market Value Forecast, by Product, 2017–2031

                    10.5.8.1.1. Latex Agglutination Tests

                    10.5.8.1.2. Lateral Flow Assay

                    10.5.8.1.3. PCR Assay

                    10.5.8.1.4. ELISA Tests

                    10.5.8.1.5. Culture Test

                    10.5.8.1.6. Others

                10.5.8.2. Market Value Forecast, by Type, 2017–2031

                    10.5.8.2.1. Syndromic Full Multiplex Panel

                    10.5.8.2.2. Low Plex Panel

                10.5.8.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.8.3.1. Hospitals

                    10.5.8.3.2. Diagnostic Centers

                    10.5.8.3.3. Others

            10.5.9. Sweden

                10.5.9.1. Market Value Forecast, by Product, 2017–2031

                    10.5.9.1.1. Latex Agglutination Tests

                    10.5.9.1.2. Lateral Flow Assay

                    10.5.9.1.3. PCR Assay

                    10.5.9.1.4. ELISA Tests

                    10.5.9.1.5. Culture Test

                    10.5.9.1.6. Others

                10.5.9.2. Market Value Forecast, by Type, 2017–2031

                    10.5.9.2.1. Syndromic Full Multiplex Panel

                    10.5.9.2.2. Low Plex Panel

                10.5.9.3. Market Value Forecast, by End-user, 2017-2031

                    10.5.9.3.1. Hospitals

                    10.5.9.3.2. Diagnostic Centers

                    10.5.9.3.3. Others

            10.5.10. Denmark

                10.5.10.1. Market Value Forecast, by Product, 2017–2031

                    10.5.10.1.1. Latex Agglutination Tests

                    10.5.10.1.2. Lateral Flow Assay

                    10.5.10.1.3. PCR Assay

                    10.5.10.1.4. ELISA Tests

                    10.5.10.1.5. Culture Test

                    10.5.10.1.6. Others

                10.5.10.2. Market Value Forecast, by Type, 2017–2031

                    10.5.10.2.1. Syndromic Full Multiplex Panel

                    10.5.10.2.2. Low Plex Panel

                10.5.10.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.10.3.1. Hospitals

                    10.5.10.3.2. Diagnostic Centers

                    10.5.10.3.3. Others

            10.5.11. Finland

                10.5.11.1. Market Value Forecast, by Product, 2017–2031

                    10.5.11.1.1. Latex Agglutination Tests

                    10.5.11.1.2. Lateral Flow Assay

                    10.5.11.1.3. PCR Assay

                    10.5.11.1.4. ELISA Tests

                    10.5.11.1.5. Culture Test

                    10.5.11.1.6. Others

                10.5.11.2. Market Value Forecast, by Type, 2017–2031

                    10.5.11.2.1. Syndromic Full Multiplex Panel

                    10.5.11.2.2. Low Plex Panel

                10.5.11.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.11.3.1. Hospitals

                    10.5.11.3.2. Diagnostic Centers

                    10.5.11.3.3. Others

            10.5.12. Austria

                10.5.12.1. Market Value Forecast, by Product, 2017–2031

                    10.5.12.1.1. Latex Agglutination Tests

                    10.5.12.1.2. Lateral Flow Assay

                    10.5.12.1.3. PCR Assay

                    10.5.12.1.4. ELISA Tests

                    10.5.12.1.5. Culture Test

                    10.5.12.1.6. Others

                10.5.12.2. Market Value Forecast, by Type, 2017–2031

                    10.5.12.2.1. Syndromic Full Multiplex Panel

                    10.5.12.2.2. Low Plex Panel

                10.5.12.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.12.3.1. Hospitals

                    10.5.12.3.2. Diagnostic Centers

                    10.5.12.3.3. Others

            10.5.13. Switzerland

                10.5.13.1. Market Value Forecast, by Product, 2017–2031

                    10.5.13.1.1. Latex Agglutination Tests

                    10.5.13.1.2. Lateral Flow Assay

                    10.5.13.1.3. PCR Assay

                    10.5.13.1.4. ELISA Tests

                    10.5.13.1.5. Culture Test

                    10.5.13.1.6. Others

                10.5.13.2. Market Value Forecast, by Type, 2017–2031

                    10.5.13.2.1. Syndromic Full Multiplex Panel

                    10.5.13.2.2. Low Plex Panel

                10.5.13.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.13.3.1. Hospitals

                    10.5.13.3.2. Diagnostic Centers

                    10.5.13.3.3. Others

            10.5.14. Rest of Europe

                10.5.14.1. Market Value Forecast, by Product, 2017–2031

                    10.5.14.1.1. Latex Agglutination Tests

                    10.5.14.1.2. Lateral Flow Assay

                    10.5.14.1.3. PCR Assay

                    10.5.14.1.4. ELISA Tests

                    10.5.14.1.5. Culture Test

                    10.5.14.1.6. Others

                10.5.14.2. Market Value Forecast, by Type, 2017–2031

                    10.5.14.2.1. Syndromic Full Multiplex Panel

                    10.5.14.2.2. Low Plex Panel

                10.5.14.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.14.3.1. Hospitals

                    10.5.14.3.2. Diagnostic Centers

                    10.5.14.3.3. Others

        10.6. Market Attractiveness Analysis

            10.6.1. By Product

            10.6.2. By Type

            10.6.3. By End-user

            10.6.4. By Country

    11. Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2017–2031

            11.2.1. Latex Agglutination Tests

            11.2.2. Lateral Flow Assay

            11.2.3. PCR Assay

            11.2.4. ELISA Tests

            11.2.5. Culture Test

            11.2.6. Others

        11.3. Market Value Forecast, by Type, 2017–2031

            11.3.1. Syndromic Full Multiplex Panel

            11.3.2. Low Plex Panel

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospitals

            11.4.2. Diagnostic Centers

            11.4.3. Others

        11.5. Market Value Forecast, by Country, 2017–2031

            11.5.1. GCC Countries

                11.5.1.1. Market Value Forecast, by Product, 2017–2031

                    11.5.1.1.1. Latex Agglutination Tests

                    11.5.1.1.2. Lateral Flow Assay

                    11.5.1.1.3. PCR Assay

                    11.5.1.1.4. ELISA Tests

                    11.5.1.1.5. Culture Test

                    11.5.1.1.6. Others

                11.5.1.2. Market Value Forecast, by Type, 2017–2031

                    11.5.1.2.1. Syndromic Full Multiplex Panel

                    11.5.1.2.2. Low Plex Panel

                11.5.1.3. Market Value Forecast, by End-user, 2017–2031

                    11.5.1.3.1. Hospitals

                    11.5.1.3.2. Diagnostic Centers

                    11.5.1.3.3. Others

            11.5.2. South Africa

                11.5.2.1. Market Value Forecast, by Product, 2017–2031

                    11.5.2.1.1. Latex Agglutination Tests

                    11.5.2.1.2. Lateral Flow Assay

                    11.5.2.1.3. PCR Assay

                    11.5.2.1.4. ELISA Tests

                    11.5.2.1.5. Culture Test

                    11.5.2.1.6. Others

                11.5.2.2. Market Value Forecast, by Type, 2017–2031

                    11.5.2.2.1. Syndromic Full Multiplex Panel

                    11.5.2.2.2. Low Plex Panel

                11.5.2.3. Market Value Forecast, by End-user, 2017–2031

                    11.5.2.3.1. Hospitals

                    11.5.2.3.2. Diagnostic Centers

                    11.5.2.3.3. Others

            11.5.3. Rest of Middle East & Africa

                11.5.3.1. Market Value Forecast, by Product, 2017–2031

                    11.5.3.1.1. Latex Agglutination Tests

                    11.5.3.1.2. Lateral Flow Assay

                    11.5.3.1.3. PCR Assay

                    11.5.3.1.4. ELISA Tests

                    11.5.3.1.5. Culture Test

                    11.5.3.1.6. Others

                11.5.3.2. Market Value Forecast, by Type, 2017–2031

                    11.5.3.2.1. Syndromic Full Multiplex Panel

                    11.5.3.2.2. Low Plex Panel

                11.5.3.3. Market Value Forecast, by End-user, 2017–2031

                    11.5.3.3.1. Hospitals

                    11.5.3.3.2. Diagnostic Centers

                    11.5.3.3.3. Others

        11.6. Market Attractiveness Analysis

            11.6.1. By Product

            11.6.2. By Type

            11.6.3. By End-user

            11.6.4. By Country

    12. Competition Landscape

        12.1. Company Profiles

            12.1.1. Thermo Fisher Scientific, Inc.

                12.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.1.2. Product Portfolio

                12.1.1.3. SWOT Analysis

                12.1.1.4. Strategic Overview

            12.1.2. BioFire Diagnostics

                12.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.2.2. Product Portfolio

                12.1.2.3. SWOT Analysis

                12.1.2.4. Strategic Overview

            12.1.3. Fast Track Diagnostics Ltd. (FTD) – Siemens Healthineers

                12.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.3.2. Product Portfolio

                12.1.3.3. SWOT Analysis

                12.1.3.4. Strategic Overview

            12.1.4. Bio-Rad Laboratories, Inc.

                12.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.4.2. Product Portfolio

                12.1.4.3. SWOT Analysis

                12.1.4.4. Strategic Overview

            12.1.5. IMMY

                12.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.5.2. Product Portfolio

                12.1.5.3. SWOT Analysis

                12.1.5.4. Strategic Overview

            12.1.6. Nanosphere (Luminex Corporation)

                12.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.6.2. Product Portfolio

                12.1.6.3. SWOT Analysis

                12.1.6.4. Strategic Overview

            12.1.7. Seegene, Inc.

                12.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.7.2. Product Portfolio

                12.1.7.3. SWOT Analysis

                12.1.7.4. Strategic Overview

            12.1.8. Qnostics

                12.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.8.2. Product Portfolio

                12.1.8.3. SWOT Analysis

                12.1.8.4. Strategic Overview

            12.1.9. ELITechGroup

                12.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.9.2. Product Portfolio

                12.1.9.3. SWOT Analysis

                12.1.9.4. Strategic Overview

            12.1.10. Abbott Laboratories

                12.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.1.10.2. Product Portfolio

                12.1.10.3. SWOT Analysis

                12.1.10.4. Strategic Overview

            12.1.11. Other Prominent Players

    List of Table

    Table 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 06: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 07: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-User, 2017–2031

    Table 08: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 09: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 10: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 11: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 12: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 13: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 14: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 15: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 16: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 17: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 18: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 19: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 20: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 21: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 22: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 23: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 24: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 25: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 26: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 27: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 28: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 29: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 30: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 31: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 32: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 33: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 34: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 35: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 36: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 37: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 38: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 39: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 40: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 41: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 42: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 43: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 44: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 45: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 46: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 47: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 48: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 49: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 50: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 51: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 52: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 53: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 54: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 55: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 56: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 57: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 58: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 59: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 60: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 61: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 62: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

    Table 63: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figure

    Figure 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Product Type (2020)

    Figure 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by End-user (2020)

    Figure 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Panel Type (2020)

    Figure 05: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Region (2020)

    Figure 06: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 07: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Latex Agglutination Tests, 2017–2031

    Figure 08: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Lateral Flow Assay, 2017–2031

    Figure 09: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by PCR Assay, 2017–2031

    Figure 10: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by ELISA Tests, 2017–2031

    Figure 11: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Culture Test, 2017–2031

    Figure 12: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by others, 2017–2031

    Figure 13: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 14: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 15: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Syndromic Full Multiplex Panel, 2017–2031

    Figure 16: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Low Plex Panel, 2017–2031

    Figure 17: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 18: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 19: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Hospitals, 2017–2031

    Figure 20: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031

    Figure 21: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 22: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 23: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Region, 2020 and 2031

    Figure 24: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Region, 2021-2031

    Figure 25: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 26: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 27: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 28: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 29: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-User, 2020 and 2031

    Figure 30: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-User, 2021–2031

    Figure 31: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Country, 2020 and 2031

    Figure 32: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country, 2021–2031

    Figure 33: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 34: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 35: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 36: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 37: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 38: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 39: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 40: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 41: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 42: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 43: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 44: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 45: France Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 46: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 47: France Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 48: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 49: France Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 50: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 51: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 52: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 53: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 54: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 55: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 56: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 57: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 58: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 59: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 60: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 61: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 62: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 63: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 64: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 65: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 66: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 67: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 68: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 69: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 70: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 71: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 72: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 73: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 74: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 75: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 76: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 77: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 78: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 79: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 80: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 81: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 82: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 83: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 84: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 85: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 86: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 87: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 88: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 89: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 90: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 91: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 92: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 93: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 94: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 95: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 96: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 97: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 98: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 99: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 100: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 101: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 102: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 103: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 104: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 105: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 106: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 107: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 108: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 109: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 110: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 111: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 112: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 113: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 114: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 115: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 116: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 117: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 118: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 119: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 120: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 121: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 122: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 123: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

    Figure 124: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 125: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 126: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 127: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 128: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 129: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 130: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 131: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 132: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 133: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 134: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 135: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 136: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 137: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031

    Figure 138: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031

    Figure 139: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031

    Figure 140: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031

    Figure 141: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 142: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031

Copyright © Transparency Market Research, Inc. All Rights reserved